Implication of VHL, ERK5, and HIF-1alpha in clear cell renal cell carcinoma: Molecular basis

dc.contributor.authorSerrano-Oviedo, Leticia
dc.contributor.authorGiménez-Bachs, José Miguel
dc.contributor.authorNam-Cha, Syong Hyun
dc.contributor.authorCimas, Francisco J.
dc.contributor.authorGarcía-Cano, Jesús
dc.contributor.authorSánchez-Prieto, Ricardo
dc.contributor.authorSalinas-Sánchez, Antonio S.
dc.date.accessioned2017-05-12T08:33:58Z
dc.date.available2017-11-08T23:01:27Z
dc.date.issued2016-11-08
dc.date.updated2017-05-12T08:33:58Z
dc.description.abstractObjectives: To determine the expression status of several proteins related to VHL gene function and its relationship with common clinicopathological parameters. Material and methods: Observational, analytical, cross-sectional study with 50 patients diagnosed with clear cell renal cell carcinoma. The study analyzed VHL mutations and hypermethylation as well as protein expression of VHL, CA-IX, HIF-1alpha, VEGF, ERK1/2, and ERK5, relating them to clinical variables. A bivariate and multivariate descriptive logistical regression analysis was performed, using the presence of metastasis at diagnosis as dependent variable. Results: The study identified 13 (26%) VHL mutations related to nuclear grade (P = 0.036). VHL hypermethylation was found in 20% of cases. VHL expression was associated with the presence of mutations (P = 0.013), and the absence of expression was associated with nuclear grade and the presence of metastasis (P<0.05). HIF-1alpha was negative in only 5 cases. Vascular endothelial growth factor (VEGF) was positive in 31 of 47 cases and was associated with Fuhrman nuclear grade, presence of metastasis, and stage (P<0.05). ERK5 expression was increased in 58% of cases and associated with the presence of metastasis and more advanced stages (P<0.05). In the logistic regression analysis, the only variable remaining in the model was VEGF expression (P = 0.014). Conclusions: VEGF has prognostic value in clear cell renal cell carcinoma, and ERK5 may be a new prognostic marker in this type of tumor owing to its relationship with metastasis and more advanced stages.
dc.format.extent8 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec670347
dc.identifier.issn1078-1439
dc.identifier.urihttps://hdl.handle.net/2445/110906
dc.language.isoeng
dc.publisherElsevier Inc.
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.urolonc.2016.10.010
dc.relation.ispartofUrologic Oncology-Seminars and Original Investigations, 2017, vol. 35, num. 3, p. 114.e15-114.e22
dc.relation.urihttps://doi.org/10.1016/j.urolonc.2016.10.010
dc.rightscc-by-nc-nd (c) Elsevier Inc. , 2016
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es
dc.sourceArticles publicats en revistes (Ciències Fisiològiques)
dc.subject.classificationProteïnes
dc.subject.classificationBiologia molecular
dc.subject.classificationMarcadors tumorals
dc.subject.classificationCàncer de ronyó
dc.subject.classificationMetàstasi
dc.subject.otherProteins
dc.subject.otherMolecular biology
dc.subject.otherTumor markers
dc.subject.otherRenal cancer
dc.subject.otherMetastasis
dc.titleImplication of VHL, ERK5, and HIF-1alpha in clear cell renal cell carcinoma: Molecular basis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
670347.pdf
Mida:
670.71 KB
Format:
Adobe Portable Document Format